Needham Investment Management LLC reduced its position in Corium International Inc (NASDAQ:CORI) by 20.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 437,188 shares of the biopharmaceutical company’s stock after selling 112,336 shares during the period. Corium International comprises about 1.1% of Needham Investment Management LLC’s portfolio, making the stock its 29th biggest holding. Needham Investment Management LLC owned about 1.21% of Corium International worth $4,202,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of CORI. Renaissance Technologies LLC raised its position in shares of Corium International by 14.0% in the fourth quarter. Renaissance Technologies LLC now owns 96,900 shares of the biopharmaceutical company’s stock valued at $931,000 after buying an additional 11,900 shares during the last quarter. Geode Capital Management LLC boosted its stake in Corium International by 6.0% during the fourth quarter. Geode Capital Management LLC now owns 223,536 shares of the biopharmaceutical company’s stock worth $2,147,000 after buying an additional 12,745 shares during the period. Schwab Charles Investment Management Inc. lifted its position in shares of Corium International by 47.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock worth $476,000 after purchasing an additional 15,909 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in shares of Corium International during the second quarter worth about $158,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Corium International by 33.7% during the third quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock worth $980,000 after purchasing an additional 22,285 shares in the last quarter. Hedge funds and other institutional investors own 88.58% of the company’s stock.
In other Corium International news, major shareholder Perceptive Advisors Llc purchased 50,350 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was bought at an average price of $11.83 per share, with a total value of $595,640.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Life Sciences Maste Perceptive purchased 510,000 shares of the firm’s stock in a transaction dated Thursday, January 18th. The stock was acquired at an average cost of $12.54 per share, with a total value of $6,395,400.00. The disclosure for this purchase can be found here. Corporate insiders own 30.80% of the company’s stock.
Several brokerages recently weighed in on CORI. Zacks Investment Research raised shares of Corium International from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. ValuEngine raised shares of Corium International from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. BidaskClub lowered shares of Corium International from a “buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright set a $14.00 price objective on shares of Corium International and gave the company a “buy” rating in a research report on Friday, February 9th. Finally, Needham & Company LLC boosted their target price on shares of Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, November 20th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $12.86.
Corium International Inc (CORI) traded up $0.06 during midday trading on Wednesday, reaching $11.92. The company’s stock had a trading volume of 390,828 shares, compared to its average volume of 302,091. The stock has a market cap of $430.60, a PE ratio of -7.59 and a beta of 1.50. Corium International Inc has a 52-week low of $3.50 and a 52-week high of $13.93. The company has a debt-to-equity ratio of 5.91, a quick ratio of 1.34 and a current ratio of 1.40.
Corium International (NASDAQ:CORI) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.06. The company had revenue of $9.32 million for the quarter, compared to analyst estimates of $7.48 million. Corium International had a negative return on equity of 403.15% and a negative net margin of 148.07%. equities analysts anticipate that Corium International Inc will post -1.43 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Needham Investment Management LLC Sells 112,336 Shares of Corium International Inc (NASDAQ:CORI)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/03/14/needham-investment-management-llc-cuts-position-in-corium-international-inc-cori.html.
Corium International Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.